Cervical Dystonia Clinical Trial
Official title:
Phase II, Double Blind, Randomized, Placebo Controlled Trial of Dronabinol for the Treatment of Cervical Dystonia
Cervical dystonia (CD) is characterized by abnormal, involuntary sustained cervical muscles contractions associated with twisting movements and abnormal postures of the neck that can be quite disabling. Currently there are no good oral medications for the treatment of CD. While botulinum toxin injections are effective in most, they require repeat injections and there are some patients who either stop responding or who never respond at all. Therefore, better treatments are needed. While the underlying mechanisms of dystonia are not entirely known, there is some information suggesting that it is ude to an underactivity of a chemical compound, GABA, that is located in the basal ganglia. Cannabinoids are a compound than can enhance transmission of GABA, and thus, may alleviate the symptoms of dystonia. Dronabinol, one such cannabinoid, has been widely used to treat anorexia and nausea in chemotherapeutic patients. The aim of this study, therefore, is to study the effect of dronabinol on cervical dystonia
Status | Unknown status |
Enrollment | 38 |
Est. completion date | December 2009 |
Est. primary completion date | November 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - 18-75 year old male and female patients with idiopathic cervical dystonia - Exclusion Criteria: - Secondary causes of dystonia; history of substance abuse, psychosis, ischemic heart disease, symptomatic postural hypotension, liver disease (LFTs > 2 times normal), renal disease - Women who are pregnant or plan on becoming pregnant during the course of the trial - Use of botulinum toxin as a treatment for cervical dystonia in the preceding 4 months - Use of other GABA mediated drugs including: gabapentin, phenobarbital, benzodiazepines, or baclofen - Use of other cannabinoids in the preceding month - Refusal to refrain from use of other cannabinoid compounds during the course of the trial - Refusal to refrain from operating heavy machinery or driving during the course of the trial |
Country | Name | City | State |
---|---|---|---|
Canada | Toronto Western Hospital | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
University Health Network, Toronto | Dystonia Medical Research Foundation |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)with 3 weeks of active treatment compared to placebo | beginning and end of each treatment | ||
Secondary | To determine the rate and severity of adverse events within and between participants | Beginning and end of each treatment | ||
Secondary | To observe changes within and between participants in the Global Impression Scale (GIS) | End of each treatment | ||
Secondary | To observe changes within and between participants in the Visual Analog Pain Scale | beginning and end of each treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03617367 -
Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)
|
Phase 3 | |
Not yet recruiting |
NCT04057911 -
A Trial of Non-invasive Stimulation in Cervical Dystonia
|
N/A | |
Withdrawn |
NCT02180139 -
tDCS in Cervical Dystonia
|
N/A | |
Completed |
NCT00541905 -
Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia
|
Phase 4 | |
Not yet recruiting |
NCT05715138 -
Comparison of Pallidal With Subthalamic Deep Brain Stimulation for Cervical Dystonia
|
N/A | |
Completed |
NCT02131467 -
Safety and Tolerability of Perampanel in Cervical Dystonia
|
Phase 1/Phase 2 | |
Completed |
NCT02959645 -
Assessment of Brain Activities in Cervical Dystonia
|
||
Completed |
NCT03805152 -
Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia
|
Phase 3 | |
Completed |
NCT04949594 -
Relief of Pain in Patients With Cervical Dystonia Through the Use of Transcutaneous Electric Nerve Stimulation (TENS)
|
||
Recruiting |
NCT01664013 -
The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients
|
Phase 4 | |
Completed |
NCT00447772 -
Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia
|
Phase 3 | |
Completed |
NCT00210431 -
Post Marketing Surveillance Study of Dysport
|
||
Completed |
NCT05157100 -
Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia
|
Phase 4 | |
Completed |
NCT00257660 -
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
|
Phase 3 | |
Completed |
NCT05103202 -
Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
|
||
Terminated |
NCT00760318 -
Keppra for Cervical Dystonia
|
Phase 2 | |
Completed |
NCT00323765 -
Plasticity in Cervical Dystonia
|
N/A | |
Completed |
NCT04171258 -
Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Patients With Cervical Dystonia
|
Phase 1 | |
Completed |
NCT04849988 -
A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia
|
Phase 2 | |
Completed |
NCT03471923 -
Non-Motor Features of Cervical Dystonia (CD)
|